NEWCASTLE B1 + BRON MASS

Indications

• Immunization against infectious diseases
• Prevention of diseases such as measles, mumps, rubella, and yellow fever
• Use in vaccine formulations for public health initiatives

Dosage

Children: Refer to the BNF for Children or specific vaccine guidelines for paediatric dosing recommendations, as doses can vary based on the vaccine and the child's age.

Adults: Refer to specific vaccine guidelines for adult dosing recommendations, as doses can vary based on the vaccine and public health protocols.

Mechanism of action

Attenuated vaccines stimulate an immune response by mimicking a natural infection. The attenuated pathogens replicate in the host, prompting the immune system to produce antibodies and memory cells without causing disease. This process enhances immunological memory and provides long-term protection against the corresponding disease.

Pharmacodynamics

The pharmacodynamic effects of attenuated vaccines primarily include the activation of both humoral and cellular immunity. The presence of weakened pathogens leads to the production of neutralizing antibodies, activation of T-helper cells, and development of cytotoxic T lymphocyte responses, thereby preparing the immune system for future encounters with the actual pathogen.

Pharmacokinetics

The pharmacokinetics of attenuated vaccines involve their administration via various routes, such as subcutaneous or intramuscular injections. After administration, attenuated organisms replicate at the site of injection, leading to systemic exposure and immune activation. The duration of immunity can vary depending on the vaccine but generally provides long-lasting protection through immunological memory.

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Caution is advised; consult a healthcare provider before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Acute bronchitis
• Chronic bronchitis
• Bronchiectasis
• Chronic obstructive pulmonary disease (COPD)

Dosage

Children: Refer to BNF for Children for appropriate dosing based on the child's age, weight, and the severity of the condition.

Adults: Refer to specific treatment guidelines or BNF for dosing recommendations based on the severity of the condition and the type of medication used.

Mechanism of action

In bronchitis, the inflammation leads to hypersecretion of mucus and bronchoconstriction. Treatment often includes bronchodilators to relax airway muscles and anti-inflammatory agents to reduce swelling. In cases of bacterial bronchitis, antibiotics may be used to target the offending pathogens.

Pharmacodynamics

The pharmacodynamics of drugs used in bronchitis focus on reducing inflammation and bronchoconstriction, facilitating easier breathing. Bronchodilators work by stimulating beta-adrenergic receptors to induce bronchodilation, while corticosteroids reduce inflammatory responses in the airways.

Pharmacokinetics

The pharmacokinetics of drugs prescribed for bronchitis vary. For example, bronchodilators are rapidly absorbed and act within minutes, while corticosteroids may take longer to exert their full effects. The distribution of these drugs occurs systemically, with metabolism primarily in the liver and excretion through urine.

Pregnancy

Consult a healthcare professional before use, as safety during pregnancy has not been fully established.

Breast-feeding

Consult a healthcare professional before use, as it is unclear if the drug passes into breast milk.

Storage

Store in a cool, dry place away from direct sunlight.

Dosage

Children: Refer to specific medications used to treat the particular disease for dosing information.

Adults: Refer to specific medications used to treat the particular disease for dosing information.

Mechanism of action

The mechanism of action varies significantly depending on the specific disease in question. For infectious diseases, pathogens may interact with host cells, leading to inflammation, immune response activation, or tissue damage. Chronic diseases often involve complex interactions between genetic factors, lifestyle choices, and environmental influences. For example, in autoimmune diseases, the immune system mistakenly targets healthy cells, leading to inflammation and tissue destruction.

Pharmacodynamics

Pharmacodynamics of disease involves understanding how the disease state affects physiological functions and the body's response to treatment. In infectious diseases, the presence of pathogens can lead to altered immune responses, while chronic diseases may involve changes in metabolic pathways, hormonal balances, or cellular functions. Medications targeting disease processes aim to restore normal function, alleviate symptoms, or eradicate pathogens.

Pharmacokinetics

Pharmacokinetics is not applicable to the term 'disease' as it refers to the movement of drugs within the body, including absorption, distribution, metabolism, and excretion of specific medications used to treat diseases. Each medication will have its own pharmacokinetic profile depending on its chemical properties and the disease being treated.

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Indications

• Bacterial infections
• Viral infections
• Fungal infections
• Parasitic infections
• Sepsis
• Pneumonia
• Urinary tract infections
• Skin and soft tissue infections

Dosage

Children: Refer to specific drug monographs for dosing information based on the type of infection and child's age and weight.

Adults: Refer to specific drug monographs for dosing information based on the type of infection and pathogen involved.

Mechanism of action

The mechanism of action of antimicrobial agents varies widely depending on the class of drug. For example, antibiotics may inhibit cell wall synthesis, protein synthesis, or nucleic acid synthesis in bacteria. Antivirals often target viral replication processes, while antifungal agents disrupt cell membrane integrity or inhibit essential metabolic pathways in fungi.

Pharmacodynamics

Pharmacodynamics of infectious disease treatments involves understanding the drug's effects on the pathogen, including the minimum inhibitory concentration (MIC) that inhibits bacterial growth, or the time and concentration needed to effectively reduce viral load. The efficacy of the antimicrobial therapy is influenced by factors such as the site of infection, the immune response of the host, and the susceptibility profile of the pathogen.

Pharmacokinetics

Pharmacokinetics of antimicrobial agents encompasses absorption, distribution, metabolism, and excretion. For instance, antibiotics may be well absorbed orally but have variable bioavailability. Distribution can be affected by tissue permeability and protein binding. Metabolism may occur in the liver, and excretion is primarily renal, influencing dosing in patients with renal impairment.

Pregnancy

Consult healthcare professional; safety varies by specific infectious agent and treatment.

Breast-feeding

Consult healthcare professional; safety varies by specific infectious agent and treatment.

Storage

Store in a cool, dry place, away from direct sunlight; specific storage may vary by formulation.

Indications

• Measles
• Mumps
• Rubella
• Varicella (chickenpox)
• Yellow fever
• Rotavirus
• Intranasal influenza

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and vaccine type.

Adults: Refer to specific product guidelines for dosing information, as it can vary by vaccine type and brand.

Mechanism of action

Live vaccines work by introducing a weakened or attenuated form of a pathogen into the body. This stimulates the immune system to recognize and respond to the pathogen, leading to the production of antibodies and memory cells that provide long-term protection against future infections by the same pathogen.

Pharmacodynamics

The pharmacodynamics of live vaccines involve the activation of both humoral and cellular immunity. Following vaccination, the immune system generates a robust response, including the production of specific antibodies and the activation of T cells that can recognize and eliminate infected cells. This dual action helps establish long-term immunity.

Pharmacokinetics

The pharmacokinetics of live vaccines vary depending on the specific vaccine. Generally, the vaccine is administered via injection, allowing the live attenuated organisms to enter the bloodstream. The immune response typically begins within days and can last for years, depending on the vaccine. Live vaccines are usually stored under refrigeration to maintain their viability, and they should be administered within their expiration dates.

Interactions

• livevaccines + abrocitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + baricitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + filgotinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + dexrazoxane: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + iron chelators: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ponesimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + upadacitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + diroximelfumarate: Moderate (increases risk of generalised infection (possibly life-threatening))

Indications

• Vaccination
• Antibiotic therapy
• Hormone replacement therapy
• Enzyme replacement therapy
• Immunotherapy

Dosage

Children: Refer to specific drug information for dosing guidelines, as this varies widely based on the active ingredient and indication.

Adults: Refer to specific drug information for dosing guidelines, as this varies widely based on the active ingredient and indication.

Mechanism of action

Lyophilization itself does not have a mechanism of action, as it is a preservation technique rather than a pharmacologically active process. The mechanism of action of the lyophilized drug will depend on the specific active pharmaceutical ingredient (API) that has been lyophilized. For example, if the lyophilized drug is a vaccine, its mechanism may involve the stimulation of the immune response through the introduction of antigens.

Pharmacodynamics

The pharmacodynamics of a lyophilized drug will vary based on the specific formulation and active ingredients. Generally, once reconstituted, the pharmacodynamic properties will reflect those of the non-lyophilized form. Factors such as bioavailability, receptor binding, and the drug's effects on physiological systems will be determined by the specific drug's characteristics.

Pharmacokinetics

The pharmacokinetics of a lyophilized drug will also depend on the specific API. Once reconstituted, the drug's absorption, distribution, metabolism, and excretion (ADME) profile will align with that of the non-lyophilized version. The freeze-drying process is designed to minimize degradation, maintaining the pharmacokinetic properties of the drug post-reconstitution.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering during breastfeeding. The effects on a nursing infant are not known.

Storage

Store in a cool, dry place. Protect from light and moisture. Follow specific storage recommendations for individual formulations.

Indications

• Prevention of Newcastle disease in poultry
• Potential oncolytic therapy in cancer treatment

Dosage

Children: Refer to specific treatment protocols or clinical guidelines for dosages, as they may vary based on the context of use.

Adults: Refer to specific treatment protocols or clinical guidelines for dosages, as they may vary based on the context of use.

Mechanism of action

Newcastle disease virus exerts its effects primarily through the induction of apoptosis in infected cells and the activation of the host immune system. The virus binds to specific receptors on the surface of host cells, facilitating viral entry and replication. It leads to the release of pro-inflammatory cytokines and enhances the anti-tumor immune response in the context of oncolytic therapies.

Pharmacodynamics

The pharmacodynamics of Newcastle disease virus involves its ability to replicate in tumor cells, leading to cell lysis and release of viral progeny that can further infect and destroy adjacent tumor cells. The host's immune system is subsequently activated, enhancing the overall anti-tumor response.

Pharmacokinetics

The pharmacokinetics of Newcastle disease virus is complex, as it involves viral replication and dissemination within the host. Following administration, the virus replicates at the site of infection, with peak viral loads observed at various time points depending on the route of administration and the host's immune status. The virus is typically cleared by the immune system over time, although its persistence can vary based on the type of host cells infected.

Pregnancy

Safety in pregnancy has not been established. Use with caution and only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Safety during breastfeeding is not well established. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight and heat. Follow specific storage requirements if available.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.